ICR: A+
Outlook: Stable
Merck is one of the largest global research-based pharmaceutical companies. The company's differentiated research capabilities consistently drive innovation and successful new drug development, with current new product pipeline revenue opportunity estimated at over $50 billion (non-risk adjusted). In 2023, the Oncology portfolio accounted for 46% of total sales (of which Keytruda was 42%), Vaccines accounted for 22%, Hospital Acute Vare accounted for 6%, a broad suite of other pharmaceutical categories (Cardiovascular, Virology, Neuroscience, Immunology, Diabetes) accounted for 17%, and animal health products accounted for 9%.
ICR: A+
Outlook: Stable
Merck is one of the largest global research-based pharmaceutical companies. The company's differentiated research capabilities consistently drive innovation and successful new drug development, with current new product pipeline revenue opportunity estimated at over $50 billion (non-risk adjusted). In 2023, the Oncology portfolio accounted for 46% of total sales (of which Keytruda was 42%), Vaccines accounted for 22%, Hospital Acute Vare accounted for 6%, a broad suite of other pharmaceutical categories (Cardiovascular, Virology, Neuroscience, Immunology, Diabetes) accounted for 17%, and animal health products accounted for 9%.
Image 1 of 1